Cooperativity of HIV-specific cytolytic CD4 T cells and CD8 T cells in control of HIV viremia

Journal of Virology

Volumn 89, Issue 15, 2015, Pages 7494-7505

  Johnson, Susan ^a,b   Eller, Michael ^a,b   Teigler, Jeffrey E ^a,b   Maloveste, Sebastien M ^a,b,e   Schultz, Bruce T ^a,b   Soghoian, Damien Z ^c   Lu, Richard ^a,b   Oster, Alexander F ^a,b   Chenine, Agnès Laurence ^a,b   Alter, Galit ^c   Dittmer, Ulf ^d   Marovich, Mary ^a,b,f   Robb, Merlin L ^a,b   Michael, Nelson L ^a,b   Bolton, Diane ^a,b   Streeck, Hendrik ^a,b,d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e Amplimmune Inc   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD161 ANTIGEN; CD45RO ANTIGEN; CD57 ANTIGEN; GRANZYME B; HLA B27 ANTIGEN; INTERLEUKIN 7 RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN; T BOX TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION CONTROL; MALE; NATURAL KILLER CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; VIRAL CLEARANCE; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; CELL CULTURE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HIV INFECTIONS; HIV-1; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD; VIREMIA;

EID: 84937677838     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00438-15     Document Type: Article

References (38)

1. Soghoian DZ, Streeck H. 2010. Cytolytic CD4+ T cells in viral immunity. Expert Rev Vaccines 9:1453-1463. http://dx.doi.org/10.1586/erv.10.132.
2. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN. 2012. Preexisting influenzaspecific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18:274-280. http://dx.doi.org/10.1038/nm.2612.
3. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703. http://dx.doi.org/10.1056/NEJMoa0800251.
4. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, Hill BJ, Roederer M, Douek DC, Koup RA. 2006. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 203:2865-2877. http://dx.doi.org/10.1084/jem.20052246.
5. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, Ranasinghe S, Lindqvist M, Davis I, Lane K, Rychert J, Rosenberg ES, Piechocka-Trocha A, Brass AL, Brenchley JM, Walker BD, Streeck H. 2012. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med 4:123ra125. http://dx.doi.org/10.1126/scitranslmed.3003165.
6. McDavid A, Finak G, Chattopadyay PK, Dominguez M, Lamoreaux L, Ma SS, Roederer M, Gottardo R. 2013. Data exploration, quality control and testing in single-cell qPCR-based gene expression experiments. Bioinformatics 29:461-467. http://dx.doi.org/10.1093/bioinformatics/bts714.
7. Lee SA, Sinclair E, Hatano H, Hsue PY, Epling L, Hecht FM, Bangsberg DR, Martin JN, McCune JM, Deeks SG, Hunt PW. 2014. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One 9:e89444. http://dx.doi.org/10.1371/journal.pone.0089444.
8. Petrovas C, Chaon B, Ambrozak DR, Price DA, Melenhorst JJ, Hill BJ, Geldmacher C, Casazza JP, Chattopadhyay PK, Roederer M, Douek DC, Mueller YM, Jacobson JM, Kulkarni V, Felber BK, Pavlakis GN, Katsikis PD, Koup RA. 2009. Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J Immunol 183:1120-1132. http://dx.doi.org/10.4049/jimmunol.0900182.
9. White MJ, Nielsen CM, McGregor RH, Riley EH, Goodier MR. 2014. Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens. Immunology 142:140-150. http://dx.doi.org/10.1111/imm.12239.
10. Huang W, Kachapati K, Adams D, Wu Y, Leung PS, Yang GX, Zhang W, Ansari AA, Flavell RA, Gershwin ME, Ridgway WM. 2014. Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1+ CD8 effector cells and defective T regulatory cells. J Autoimmun 50:123-134. http://dx.doi.org/10.1016/j.jaut.2014.01.034.
11. Beyersdorf NB, Ding X, Karp K, Hanke T. 2001. Expression of inhibitory "killer cell lectin-like receptor G1" identifies unique subpopulations of effector and memory CD8 T cells. Eur J Immunol 31:3443-3452. http://dx.doi.org/10.1002/1521-4141(200112)31:12<3443::AID-IMMU3443>3.0.CO;2-J.
12. Miller SA, Weinmann AS. 2010. Molecular mechanisms by which T-bet regulates T-helper cell commitment. Immunol Rev 238:233-246. http://dx.doi.org/10.1111/j.1600-065X.2010.00952.x.
13. Placek K, Coffre M, Maiella S, Bianchi E, Rogge L. 2009. Genetic and epigenetic networks controlling T helper 1 cell differentiation. Immunology 127:155-162. http://dx.doi.org/10.1111/j.1365-2567.2009.03059.x.
14. Eshima K, Chiba S, Suzuki H, Kokubo K, Kobayashi H, Iizuka M, Iwabuchi K, Shinohara N. 2012. Ectopic expression of a T-box transcription factor, Eomesodermin, renders CD4+ Th cells cytotoxic by activating both perforin-and FasL-pathways. Immunol Lett 144:7-15. http://dx.doi.org/10.1016/j.imlet.2012.02.013.
15. Workman AM, Jacobs AK, Vogel AJ, Condon S, Brown DM. 2014. Inflam-mation enhances IL-2 driven differentiation of cytolytic CD4 T cells. PLoS One 9:e89010. http://dx.doi.org/10.1371/journal.pone.0089010.
16. Qui HZ, Hagymasi AT, Bandyopadhyay S, St Rose MC, Ramanarasimhaiah R, Menoret A, Mittler RS, Gordon SM, Reiner SL, Vella AT, Adler AJ. 2011. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol 187:3555-3564. http://dx.doi.org/10.4049/jimmunol.1101244.
17. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. 2013. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 210:743-755. http://dx.doi.org/10.1084/jem.20121190.
18. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103-6110.
19. Saez-Cirion A, Shin SY, Versmisse P, Barre-Sinoussi F, Pancino G. 2010. Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat Protoc 5:1033-1041. http://dx.doi.org/10.1038/nprot.2010.73.
20. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M, Koup RA. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417:95-98. http://dx.doi.org/10.1038/417095a.
21. Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C, Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E, Dally L, Gotch F, Walker B, Gilmour J, Hayes P. 2010. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 201:720-729. http://dx.doi.org/10.1086/650492.
22. Brenchley JM, Ruff LE, Casazza JP, Koup RA, Price DA, Douek DC. 2006. Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo. J Virol 80:6801-6809. http://dx.doi.org/10.1128/JVI.00070-06.
23. von Gegerfelt A, Valentin A, Alicea C, Van Rompay KK, Marthas ML, Montefiori DC, Pavlakis GN, Felber BK. 2010. Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus. J Immunol 185:3348-3358. http://dx.doi.org/10.4049/jimmunol.1000572.
24. Ortiz AM, Klatt NR, Li B, Yi Y, Tabb B, Hao XP, Sternberg L, Lawson B, Carnathan PM, Cramer EM, Engram JC, Little DM, Ryzhova E, Gonzalez-Scarano F, Paiardini M, Ansari AA, Ratcliffe S, Else JG, Brenchley JM, Collman RG, Estes JD, Derdeyn CA, Silvestri G. 2011. Depletion of CD4+ T cells abrogates post-peak decline of viremia in SIVinfected rhesus macaques. J Clin Invest 121:4433-4445. http://dx.doi.org/10.1172/JCI46023.
25. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450. http://dx.doi.org/10.1126/science.278.5342.1447.
26. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer MF, Heiken H, Kuhlmann B, Kaiser T, Bozkaya H, Tillmann HL, Bozdayi AM, Manns MP, Wedemeyer H. 2006. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 13:505-514. http://dx.doi.org/10.1111/j.1365-2893.2006.00723.x.
27. Akhmetzyanova I, Zelinskyy G, Schimmer S, Brandau S, Altenhoff P, Sparwasser T, Dittmer U. 2013. Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells. Cancer Immunol Immunother 62:257-271. http://dx.doi.org/10.1007/s00262-012-1329-y.
28. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH. 2012. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188: 5166-5176. http://dx.doi.org/10.4049/jimmunol.1102756.
29. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, Banica M, DiCioccio CB, Gross DA, Mao CA, Shen H, Cereb N, Yang SY, Lindsten T, Rossant J, Hunter CA, Reiner SL. 2003. Control of effectorCD8+T cell function by the transcription factor Eomesodermin. Science 302:1041-1043. http://dx.doi.org/10.1126/science.1090148.
30. Hersperger AR, Martin JN, Shin LY, Sheth PM, Kovacs CM, Cosma GL, Makedonas G, Pereyra F, Walker BD, Kaul R, Deeks SG, Betts MR. 2011. Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood 117:3799-3808. http://dx.doi.org/10.1182/blood-2010-12-322727.
31. Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, Roederer M, De Rosa SC. 2009. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol 85:88-97. http://dx.doi.org/10.1189/jlb.0208107.
32. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, Norris PJ, Nixon DF, Lanier LL. 2010. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116:3865-3874. http://dx.doi.org/10.1182/blood-2010-04-282301.
33. Palmer BE, Blyveis N, Fontenot AP, Wilson CC. 2005. Functional and phenotypic characterization of CD57+ CD4+ T cells and their association with HIV-1-induced T cell dysfunction. J Immunol 175:8415-8423. http://dx.doi.org/10.4049/jimmunol.175.12.8415.
34. Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, Meinert CL, Martin JN, McCune JM, Deeks SG, Lederman MM, Hecht FM, Hunt PW. 2014. Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis 210:374-382. http://dx.doi.org/10.1093/infdis/jiu109.
35. Muraille E. 2014. Generation of individual diversity: a too neglected fundamental property of adaptive immune system. Front Immunol 5:208. http://dx.doi.org/10.3389/fimmu.2014.00208.
36. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ. 2002. Viral immune evasion: a masterpiece of evolution. Immunogenetics 54: 527-542. http://dx.doi.org/10.1007/s00251-002-0493-1.
37. Jones RB, Yue FY, Gu XX, Hunter DV, Mujib S, Gyenes G, Mason RD, Mohamed R, MacDonald KS, Kovacs C, Ostrowski MA. 2009. Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations. J Virol 83:8722-8732. http://dx.doi.org/10.1128/JVI.00433-09.
38. Burwitz BJ, Giraldo-Vela JP, Reed J, Newman LP, Bean AT, Nimityongskul FA, Castrovinci PA, Maness NJ, Leon EJ, Rudersdorf R, Sacha JB. 2012. CD8+ and CD4+ cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controller. Retrovirology 9:91. http://dx.doi.org/10.1186/1742-4690-9-91